Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Sihuan Pharmaceutical announces that its subsidiary, Huisheng Biopharmaceutical, has received NMPA approval for its innovative Insulin Degludec and Insulin Aspart Injection, Huiyoujia, for treating type 2 diabetes in adults in China. This marks the first domestic biosimilar to Novo Nordisk’s original drug, offering a simpler administration method and mimicking near-physiological insulin secretion. The launch is expected to drive significant growth for the Group’s diabetes drug pipeline amid China’s rising diabetes prevalence.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.